Use of incretin receptor agonists in patients submitted to metabolic bariatric surgery – a systematic review and meta-analysis
Mariana Santos-Pereira, João F. Frutuoso, Sofia S. Pereira, Marta Guimarães, Mariana P. Monteiro · 2026
Read Use of incretin receptor agonists in patients submitted to metabolic bariatric surgery – a systematic review and meta-analysis by Mariana Santos-Pereira, João F. Frutuoso, Sofia S. Pereira, Marta Guimarães, Mariana P. Monteiro (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13553220.txt.
Description
Mariana Santos-Pereira and co-authors ask whether the new generation of weight-loss drugs can rescue patients whose bariatric surgery underdelivered. Their 2026 systematic review and meta-analysis gather twenty-seven studies of incretin receptor agonists, the GLP-1 family and its dual-action cousin. All were given at least a year after metabolic surgery, to patients with insufficient loss or regain.
At twelve months, total weight loss averaged about nine percent on either liraglutide or semaglutide. At six months the dual-action drug beat semaglutide by about four percentage points. No serious adverse events appeared; side effects were mostly mild gut symptoms, the class's familiar tax. The evidence base is heterogeneous and observational, which the authors flag. Still, a drug rescue changes the conversation after failed surgery, where the alternative was a riskier reoperation. This review prices the rescue for the first time in numbers.
Catalog record
| CREATOR | Mariana Santos-Pereira, João F. Frutuoso, Sofia S. Pereira, Marta Guimarães, Mariana P. Monteiro |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 48 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |